CimCure
The company develops cancer vaccines that target and destroy the tumor's network of blood vessels to stop growth and eliminate solid tumors. Utilizing proprietary Immune-Boost (iBoost) technology, they fuse foreign proteins to tumor-associated blood vessel proteins to trigger an antibody response. Their lead product, CVx1, is being advanced into clinical studies for patients with muscle-invasive bladder cancer.
Visit websiteAmsterdam, Netherlands
Biotech
Healthtech
Oncology
Immunotherapy
Funding summary
- Total raised
- €5.0M
- Funding rounds
- 1
Investors in CimCure
Investors on record for CimCure. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like CimCure?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors